Jeff Jones
Stock Analyst at Oppenheimer
(4.54)
# 1,026
Out of 5,051 analysts
291
Total ratings
41.8%
Success rate
15%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKTS Aktis Oncology | Initiated Coverage: Buy | $40 | $17.34 | +130.68% | 1 | Sep 9, 2026 | |
| PHVS Pharvaris | Reiterated: Buy | $50 → $75 | $30.89 | +142.80% | 12 | Sep 8, 2026 | |
| ALMS Alumis | Reiterated: Buy | $55 → $37 | $7.06 | +424.08% | 16 | Sep 2, 2026 | |
| PMVP PMV Pharmaceuticals | Reiterated: Buy | $5 | $1.41 | +254.61% | 18 | Sep 1, 2026 | |
| AAPG Ascentage Pharma Group International | Reiterated: Buy | $45 | $15.31 | +193.93% | 2 | Aug 21, 2026 | |
| MDWD MediWound | Reiterated: Buy | $32 → $30 | $12.56 | +138.85% | 6 | Aug 14, 2026 | |
| PTHS Pelthos Therapeutics | Reiterated: Buy | $66 → $64 | $19.52 | +227.87% | 9 | Aug 14, 2026 | |
| ACRV Acrivon Therapeutics | Reiterated: Buy | $8 | $1.90 | +321.05% | 2 | Aug 13, 2026 | |
| AVBP ArriVent BioPharma | Reiterated: Buy | $50 | $16.46 | +203.77% | 9 | Aug 13, 2026 | |
| CATX Perspective Therapeutics | Reiterated: Buy | $13 | $2.52 | +415.87% | 32 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $52 → $48 | $5.27 | +810.82% | 24 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $33 | $10.05 | +228.36% | 18 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $11 | $3.80 | +189.47% | 1 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $18.26 | +119.06% | 2 | Jun 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $1.39 | +1,698.56% | 22 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $3.60 | +177.78% | 2 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $41 → $40 | $9.61 | +316.23% | 9 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 → $7 | $3.38 | +107.10% | 4 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $86 | $29.04 | +196.14% | 7 | Apr 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.43 | - | 20 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $120 | $112.08 | +7.07% | 12 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $17 → $16 | $4.00 | n/a | 4 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 → $20 | $4.90 | n/a | 2 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.986 | n/a | 22 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.68 | n/a | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $4.30 | n/a | 7 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $0.4139 | n/a | 5 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.6888 | n/a | 4 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $0.99 | n/a | 4 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $3.00 | n/a | 3 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.000001 | n/a | 2 | Jul 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.012 | n/a | 1 | Sep 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $37 | $45.01 | n/a | 1 | Jun 22, 2021 |
Aktis Oncology
Sep 9, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $17.34
Upside: +130.68%
Pharvaris
Sep 8, 2026
Reiterated: Buy
Price Target: $50 → $75
Current: $30.89
Upside: +142.80%
Alumis
Sep 2, 2026
Reiterated: Buy
Price Target: $55 → $37
Current: $7.06
Upside: +424.08%
PMV Pharmaceuticals
Sep 1, 2026
Reiterated: Buy
Price Target: $5
Current: $1.41
Upside: +254.61%
Ascentage Pharma Group International
Aug 21, 2026
Reiterated: Buy
Price Target: $45
Current: $15.31
Upside: +193.93%
MediWound
Aug 14, 2026
Reiterated: Buy
Price Target: $32 → $30
Current: $12.56
Upside: +138.85%
Pelthos Therapeutics
Aug 14, 2026
Reiterated: Buy
Price Target: $66 → $64
Current: $19.52
Upside: +227.87%
Acrivon Therapeutics
Aug 13, 2026
Reiterated: Buy
Price Target: $8
Current: $1.90
Upside: +321.05%
ArriVent BioPharma
Aug 13, 2026
Reiterated: Buy
Price Target: $50
Current: $16.46
Upside: +203.77%
Perspective Therapeutics
Aug 11, 2026
Reiterated: Buy
Price Target: $13
Current: $2.52
Upside: +415.87%
Aug 7, 2026
Reiterated: Buy
Price Target: $52 → $48
Current: $5.27
Upside: +810.82%
Aug 7, 2026
Reiterated: Buy
Price Target: $33
Current: $10.05
Upside: +228.36%
Jul 31, 2026
Initiated Coverage: Buy
Price Target: $11
Current: $3.80
Upside: +189.47%
Jun 18, 2026
Reiterated: Buy
Price Target: $40
Current: $18.26
Upside: +119.06%
May 15, 2026
Reiterated: Buy
Price Target: $25
Current: $1.39
Upside: +1,698.56%
May 8, 2026
Reiterated: Buy
Price Target: $10
Current: $3.60
Upside: +177.78%
May 8, 2026
Reiterated: Buy
Price Target: $41 → $40
Current: $9.61
Upside: +316.23%
May 8, 2026
Reiterated: Buy
Price Target: $6 → $7
Current: $3.38
Upside: +107.10%
Apr 20, 2026
Reiterated: Buy
Price Target: $86
Current: $29.04
Upside: +196.14%
Mar 2, 2026
Rated: Hold
Price Target: n/a
Current: $1.43
Upside: -
Feb 27, 2026
Reiterated: Buy
Price Target: $120
Current: $112.08
Upside: +7.07%
Aug 15, 2025
Reiterated: Buy
Price Target: $17 → $16
Current: $4.00
Upside: n/a
Aug 14, 2025
Reiterated: Buy
Price Target: $19 → $20
Current: $4.90
Upside: n/a
Aug 8, 2025
Reiterated: Hold
Price Target: n/a
Current: $0.986
Upside: n/a
Oct 29, 2024
Rated: Hold
Price Target: n/a
Current: $2.68
Upside: n/a
Aug 14, 2024
Reiterated: Hold
Price Target: n/a
Current: $4.30
Upside: n/a
Nov 30, 2023
Reiterated: Buy
Price Target: n/a
Current: $0.4139
Upside: n/a
Nov 10, 2023
Reiterated: Hold
Price Target: n/a
Current: $0.6888
Upside: n/a
Nov 7, 2023
Reiterated: Buy
Price Target: n/a
Current: $0.99
Upside: n/a
Apr 28, 2023
Rated: Buy
Price Target: n/a
Current: $3.00
Upside: n/a
Jul 20, 2022
Downgraded: Hold
Price Target: n/a
Current: $0.000001
Upside: n/a
Sep 30, 2021
Reiterated: Hold
Price Target: n/a
Current: $0.012
Upside: n/a
Jun 22, 2021
Reiterated: Buy
Price Target: $37
Current: $45.01
Upside: n/a